Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesXORTX Therapeutics Inc

XORTX Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-04T21:00:12.445693Z
Market Cap
6.03M

Momentum Score

…

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.42
Low
9.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

XORTX Therapeutics Inc is a small-cap life sciences company on the TSX Venture Exchange that appears focused on developing therapeutics, but public information on its pipeline is limited. Long-term growth may depend on clinical progress, regulatory approvals and partnerships, which could provide milestone-driven value.

Principal risks include early-stage program and regulatory failure, limited cash and operating history leading to dilution, and low liquidity on a venture market.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-98.00%
Net Debt
-
ROCE
-156.20%
Diluted EPS TTM
-3.84

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.66M -3.31M -2.16M -6.99M -1.65M
Net income -2.66M -3.31M -2.16M -6.99M -1.65M
Selling general administrative 1.83M 2.28M 2.23M 2.29M 2.78M
Reconciled depreciation 0.11M 0.12M 0.14M 0.06M 0.02M
Ebit - - - -12.03M -2.89M
Ebitda - - - -6.93M -1.63M
Operating income -3.26M -4.12M -6.05M -9.86M -3.65M
Interest expense - - - 0.00M 0.01M
Interest income 0.04M - 0.26M 0.10M -
Net interest income 0.04M 0.12M 0.25M -0.83M -1.63M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.26M 4.12M 6.05M 9.86M 3.65M
Total other income expense net 0.56M 0.68M 3.63M 3.70M 3.63M
Net income from continuing ops -2.66M -3.31M -2.16M -6.99M -1.65M
Net income applicable to common shares - - - -9.49M -1.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.68M 4.09M 5.47M 12.34M 22.04M
Intangible assets 0.19M 0.18M 0.18M 0.20M 0.26M
Other current assets - - - - 0.71M
Total liab 0.60M 0.76M 0.83M 5.37M 5.30M
Total stockholder equity 2.08M 3.34M 4.64M 6.97M 16.74M
Other current liab 0.01M 0.57M - - 4.60M
Common stock - - - 20.61M 20.01M
Capital stock 20.18M 18.49M 17.06M 15.18M 20.01M
Retained earnings -23.82M -21.17M -17.85M -19.18M -9.69M
Other liab - - - 5.22M 4.60M
Other assets - - - 1.61M 1.61M
Cash 0.86M 2.47M 3.45M 10.41M 18.85M
Total current liabilities 0.60M 0.76M 0.29M 2.05M 0.70M
Other stockholder equity - - - 8.04M 6.42M
Property plant equipment - - - 0.13M -
Total current assets 1.26M 2.68M 4.07M 14.75M 20.17M
Net tangible assets - - - 9.20M 16.48M
Net receivables 0.08M 0.02M 0.06M 0.11M 0.05M
Accounts payable 0.40M 0.08M 0.20M 1.76M 0.41M
Non current assets total 1.42M 1.42M 1.40M 1.48M 1.86M
Capital lease obligations 0.04M 0.04M 0.01M 0.08M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.04M -0.05M -0.04M -0.04M
Change to liabilities - - - 1.26M -0.33M
Total cashflows from investing activities - - - -0.06M -0.04M
Net borrowings -0.09M -0.07M -0.07M -0.06M -0.06M
Total cash from financing activities 1.43M 2.78M -0.36M 6.43M 24.46M
Change to operating activities - - - 0.76M -1.01M
Net income -2.66M -3.31M -2.92M -9.49M -1.65M
Change in cash -1.61M -0.97M -6.99M -4.73M 18.68M
Begin period cash flow 2.47M 3.45M 10.43M 13.89M 0.17M
End period cash flow 0.86M 2.47M 3.45M 10.41M 18.85M
Total cash from operating activities -2.77M -3.68M -6.58M -11.97M -6.06M
Issuance of capital stock 2.26M 3.50M 0.00M 5.05M 22.80M
Depreciation 0.11M 0.12M 0.14M 0.08M 0.02M
Change to account receivables -0.06M 0.04M 0.02M -0.06M -0.04M
Other cashflows from financing activities - - - -0.37M -0.86M
Change to netincome - - - -4.52M -3.05M
Capital expenditures 0.06M 0.04M 0.05M 0.03M 0.03M
Change in working capital 0.34M 0.12M -1.03M 1.45M -1.38M
Stock based compensation 0.03M 0.12M 0.12M 0.47M 0.50M
Other non cash items - - - 0.00M 0.07M
Free cash flow -2.82M -3.72M -6.63M -8.86M -6.10M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

XORTX Therapeutics Inc

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

3710 - 33rd Street NW, Calgary, AB, Canada, T2L 2M1

403-455-7727

https://www.xortx.com

Name Title Year Born
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, Pres & Director 1960
Mr. Amar Keshri C.A., CPA Chief Financial Officer 1979
Nick Rigopoulos Director of Communications NA
Dr. David Sans M.B.A., Ph.D. Director of Corp. Devel. NA
Dr. Stephen Haworth M.D., MRCP Chief Medical Officer 1951
Dr. David MacDonald Ph.D. Consultant of Clinical Operations 1963
Dr. Stacy Evans M.B.A., M.D. Chief Bus. Officer NA
Ms. Charlotte May Corp. Sec. NA
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, President & Director 1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D Chief Financial Officer 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…